All In Biotech

Drug Trial Radar · NCT00297115

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)

Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The HERMES Study

Last checked: Nov 19, 2026Latest source record: Nov 7, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,568 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,568

Actual

Start

Mar 2006

Primary completion

Apr 2008

Study completion Aug 2008

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 28, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will be up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast. For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673 (toll free).

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • RoflumilastDrug

    500 mcg, once daily, oral administration in the morning

  • PlaceboDrug

    once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)Time frame: Change from baseline over 52 weeks of treatment
  2. COPD Exacerbation Rate (Moderate or Severe)Time frame: 52 weeks treatment period

Locations

287 sites in 8 countries. Site status is shown where the registry gives one.

  • Altana Pharma/Nycomed Investigational Site

    Bayou La Batre, Alabama

  • Altana Pharma/Nycomed Investigational Site

    Birmingham, Alabama

  • Altana Pharma/Nycomed Investigational Site

    Birmingham, Alabama

  • Altana Pharma/Nycomed Investigational Site

    Huntsville, Alabama

  • Altana Pharma/Nycomed Investigational Site

    Bullhead City, Arizona

  • Altana Pharma/Nycomed Investigational Site

    Phoenix, Arizona

  • Altana Pharma/Nycomed Investigational Site

    Phoenix, Arizona

  • Altana Pharma/Nycomed Investigational Site

    Fort Smith, Arkansas

  • Altana Pharma/Nycomed Investigational Site

    Little Rock, Arkansas

  • Altana Pharma/Nycomed Investigational Site

    Anaheim, California

  • Altana Pharma/Nycomed Investigational Site

    Burbank, California

  • Altana Pharma/Nycomed Investigational Site

    Carlsbad, California

  • Altana Pharma/Nycomed Investigational Site

    Fresno, California

  • Altana Pharma/Nycomed Investigational Site

    Lakewood, California

  • Altana Pharma/Nycomed Investigational Site

    Long Beach, California

  • Altana Pharma/Nycomed Investigational Site

    Los Alamitos, California

  • Altana Pharma/Nycomed Investigational Site

    Los Angeles, California

  • Altana Pharma/Nycomed Investigational Site

    Roseville, California

  • Altana Pharma/Nycomed Investigational Site

    Sacramento, California

  • Altana Pharma/Nycomed Investigational Site

    San Diego, California

  • Altana Pharma/Nycomed Investigational Site

    San Diego, California

  • Altana Pharma/Nycomed Investigational Site

    Sepulveda, California

  • Altana Pharma/Nycomed Investigational Site

    Stockton, California

  • Altana Pharma/Nycomed Investigational Site

    Denver, Colorado

  • Altana Pharma/Nycomed Investigational Site

    Waterbury, Connecticut

  • Altana Pharma/Nycomed Investigational Site

    Washington D.C., District of Columbia

  • Altana Pharma/Nycomed Investigational Site

    Clearwater, Florida

  • Altana Pharma/Nycomed Investigational Site

    DeLand, Florida

  • Altana Pharma/Nycomed Investigational Site

    Fort Lauderdale, Florida

  • Altana Pharma/Nycomed Investigational Site

    Jacksonville, Florida

  • Altana Pharma/Nycomed Investigational Site

    Miami, Florida

  • Altana Pharma/Nycomed Investigational Site

    Miami, Florida

  • Altana Pharma/Nycomed Investigational Site

    Miami Beach, Florida

  • Altana Pharma/Nycomed Investigational Site

    Ocala, Florida

  • Altana Pharma/Nycomed Investigational Site

    Ormand Beach, Florida

  • Altana Pharma/Nycomed Investigational Site

    Port Orange, Florida

  • Altana Pharma/Nycomed Investigational Site

    Tamarac, Florida

  • Altana Pharma/Nycomed Investigational Site

    Vero Beach, Florida

  • Altana Pharma/Nycomed Investigational Site

    Atlanta, Georgia

  • Altana Pharma/Nycomed Investigational Site

    Blue Ridge, Georgia

Showing 40 of 287 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.